UA67725C2 - K-252a derivatives and a method for improvement of functioning and cell survival enhancement - Google Patents

K-252a derivatives and a method for improvement of functioning and cell survival enhancement Download PDF

Info

Publication number
UA67725C2
UA67725C2 UA98126949A UA98126949A UA67725C2 UA 67725 C2 UA67725 C2 UA 67725C2 UA 98126949 A UA98126949 A UA 98126949A UA 98126949 A UA98126949 A UA 98126949A UA 67725 C2 UA67725 C2 UA 67725C2
Authority
UA
Ukraine
Prior art keywords
compound
lower alkyl
same meaning
unsubstituted
substituted
Prior art date
Application number
UA98126949A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Cephalon Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Kyowa Hakko Kogyo Kk filed Critical Cephalon Inc
Publication of UA67725C2 publication Critical patent/UA67725C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
UA98126949A 1996-06-03 1997-02-06 K-252a derivatives and a method for improvement of functioning and cell survival enhancement UA67725C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65736696A 1996-06-03 1996-06-03
PCT/US1997/009448 WO1997046565A1 (en) 1996-06-03 1997-06-02 SELECTED DERIVATIVES OF K-252a

Publications (1)

Publication Number Publication Date
UA67725C2 true UA67725C2 (en) 2004-07-15

Family

ID=24636859

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98126949A UA67725C2 (en) 1996-06-03 1997-02-06 K-252a derivatives and a method for improvement of functioning and cell survival enhancement

Country Status (18)

Country Link
US (1) US6306849B1 (no)
EP (1) EP0918777B1 (no)
JP (1) JP2000511902A (no)
CN (1) CN1198827C (no)
AT (1) ATE222912T1 (no)
AU (1) AU716656B2 (no)
BR (1) BR9711093A (no)
CA (1) CA2256633C (no)
DE (1) DE69715010T2 (no)
DK (1) DK0918777T3 (no)
ES (1) ES2183184T3 (no)
HK (1) HK1018703A1 (no)
NO (1) NO312464B1 (no)
NZ (2) NZ333018A (no)
PT (1) PT918777E (no)
RU (1) RU2205184C2 (no)
UA (1) UA67725C2 (no)
WO (1) WO1997046565A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1126855B1 (en) 1998-09-25 2007-05-09 Cephalon, Inc. Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
WO2004032852A2 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
DE60335957D1 (de) * 2002-10-08 2011-03-17 Rinat Neuroscience Corp Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
KR101250818B1 (ko) * 2002-12-24 2013-04-15 리나트 뉴로사이언스 코프. 항-ngf 항체 및 그것을 이용하는 방법
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7655231B2 (en) 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
NZ549990A (en) 2004-04-07 2009-08-28 Rinat Neuroscience Copr Methods for treating bone cancer pain by administering a nerve growth factor antagonist
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
JP5579197B2 (ja) * 2008-12-22 2014-08-27 クレアビリ ソスィエテ アノニム インドロカルバゾール化合物のポリマー結合体の合成

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554402A (en) 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Sf−2370物質ハロゲン化誘導体とその製造法
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質k−252の誘導体
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質k−252の誘導体
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ucn―01
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質k−252の誘導体
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質k−252の誘導体
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
EP0303697B1 (en) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 K−252誘導体
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
DE3835842A1 (de) 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
WO1991009034A1 (en) 1989-12-14 1991-06-27 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
JPH0586068A (ja) 1991-03-04 1993-04-06 Rikagaku Kenkyusho 新規抗生物質rk−1409、その製造法並びに抗腫瘍剤及び抗炎症剤
AU3064992A (en) 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
JP2593021B2 (ja) 1991-12-13 1997-03-19 伊藤ハム株式会社 ウシ胚の性の識別方法
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
EP0575955B1 (en) 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
JPH0673063A (ja) 1992-06-22 1994-03-15 Kyowa Hakko Kogyo Co Ltd Ucn−01誘導体
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5674867A (en) 1992-09-21 1997-10-07 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives and therapeutic method for stimulating megakaicyocyte production
US5516771A (en) 1993-05-28 1996-05-14 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
EP0703917A1 (en) 1993-06-17 1996-04-03 Novartis AG Indolocarbazole compound useful as proteinkinase c inhibitor
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
NO312464B1 (no) 2002-05-13
CA2256633C (en) 2009-04-07
EP0918777B1 (en) 2002-08-28
WO1997046565A1 (en) 1997-12-11
NZ333018A (en) 2000-05-26
JP2000511902A (ja) 2000-09-12
DE69715010D1 (de) 2002-10-02
US6306849B1 (en) 2001-10-23
DE69715010T2 (de) 2003-04-03
ATE222912T1 (de) 2002-09-15
HK1018703A1 (en) 1999-12-30
BR9711093A (pt) 1999-08-17
ES2183184T3 (es) 2003-03-16
AU3225397A (en) 1998-01-05
EP0918777A1 (en) 1999-06-02
NO985622D0 (no) 1998-12-02
NZ504097A (en) 2005-06-24
CA2256633A1 (en) 1997-12-11
CN1198827C (zh) 2005-04-27
AU716656B2 (en) 2000-03-02
CN1226893A (zh) 1999-08-25
NO985622L (no) 1999-02-02
RU2205184C2 (ru) 2003-05-27
DK0918777T3 (da) 2002-12-30
PT918777E (pt) 2003-01-31

Similar Documents

Publication Publication Date Title
UA67725C2 (en) K-252a derivatives and a method for improvement of functioning and cell survival enhancement
EP3752510B1 (en) Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
ES2744636T3 (es) Derivados de 4,5,6,7-tetrahidropirazolo[1,5-a]pirazina sustituidos como inhibidores de caseína quinasa 1 D/E
EP2444400B1 (en) Substituted polycyclic carbamoylpyridone derivative
EP2829545B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2233474B1 (en) Condensed aminodihydrothiazine derivative
KR101700267B1 (ko) 화합물
JP5755739B2 (ja) β−アミロイド産生の減少のための化合物
EP3816163A1 (en) Cell necrosis inhibitor, preparation method therefor and use thereof
CA2812363A1 (en) Substituted polycyclic carbamoyl pyridone derivative prodrug
JP2023027102A (ja) オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
JPH09505596A (ja) ラパマイシンの複素環式エステルおよびそれらを含有する医薬組成物
EP1478648A2 (en) Phosphorus-containing compounds uses thereof
AU2003210787A1 (en) Phosphorus-containing compounds & uses thereof
EA020409B1 (ru) Антагонисты рецептора cgrp
CA2829939A1 (en) Tricyclic gyrase inhibitors
WO2011050284A1 (en) Pyrazolylpyridine antiviral agents
EP3692991A1 (de) Positiv allosterische modulatoren des muskarinergen m2 rezeptors
EP4137484A1 (en) Tricyclic compounds as egfr inhibitors
EA032415B1 (ru) Замещенные бициклические соединения
CN106660992B (zh) 二甲基吡啶胺衍生物及其医药用途
EP0255028A2 (de) Neue 1,4-Benzodiazepine, ihre Herstellung und Verwendung als PAF Antagonisten
CA3170503A1 (en) Stat degraders and uses thereof
EP3818065B1 (en) Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1
JP7118354B2 (ja) 三環式化合物の結晶形及びその使用